508381579 02/09/2024

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 Assignment ID: PATI17416

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Nextgen Bioscience Co.	01/26/2024

RECEIVING PARTY DATA

Company Name:	Industry-Academic Cooperation Foundation Yonsei University	
Street Address:	50 Yonsei-ro	
City:	Seodaemun-gu, Seoul	
State/Country:	KOREA, REPUBLIC OF	
Postal Code:	03722	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	12865356

CORRESPONDENCE DATA

Fax Number: 4192497151

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4192497100

Email: kroth@marshall-melhorn.com

Correspondent Name: Kristine R. Roth Four Seagate Address Line 1: **Address Line 2:** Eighth Floor

Address Line 4: Toledo, OHIO 43604

ATTORNEY DOCKET NUMBER:	1-27908
NAME OF SUBMITTER:	Kristine Roth
SIGNATURE:	Kristine Roth
DATE SIGNED:	02/09/2024

Total Attachments: 3

source=US 8450502B2 Assignment#page1.tif source=US 8450502B2 Assignment#page2.tif source=US 8450502B2 Assignment#page3.tif

> PATENT REEL: 066428 FRAME: 0161 508381579

Docket No. 1-27908 CLIO 1083-91670

For: <u>x</u> U.S. and/or Foreign Rights

ASSIGNMENT OF INVENTION

		<u>x</u> <u>x</u>	U.S. Application Inventor(s) or Present Owner
For good and valua acknowledged,	able considerat	tion, t	he receipt of which is hereby
ASSIGNOR(S):	Inventors or pe	ersons	s or entities who own the invention
Nextgen Bioscience Co. #803-1 B-dong 670 Daewangpangyp-ro, Bundang-gu 13494 Seongnam-si, Gyeonggi-do Republic of Korea			Co. of Republic of Korea Nationality
hereby sell, assign and transfer to ASSIGNEE: Industry-Academic Cooperation Formula Yonsei University 50 Yonsei-ro.	<u>undation</u>		<u>University of Republic of Korea</u> Nationality
03722 Seodaemun-gu, Seoul Republic of Korea			
and the successors, assigns and leg	•		
countries, including all rights to clain disclosed in the invention entitled:INHIBITING ANGIOGENESIS	•		•
Name of inventor(s) <u>Ho Jeong K</u>	won, and Hye J	in Jur	ng
which is found in			

PATENT REEL: 066428 FRAME: 0162

Docket No. 1-27908 CLIO 1083-91670

	U.S. patent application executed on even date herewith;		
	U.S. provisional application No	filed on;	
	U.S. non-provisional application No	filed on;	
x	U.S. application No. <u>12/865,356</u> 35 USC 371 of international application No. <u>PC</u> on <u>Jan. 30, 2009</u> , now Patent No. 8,456	CT/KR2009/000457 filed	
	X To comply with 37 CFR 3.21 for recordal of this assignment, We/l, the Assignor(s) signing below, hereby authorize and request my/our attorne to insert the filing date and application number when they become		

and any legal equivalent thereof in a foreign country, including the right to claim priority, and in and to, all Letters Patent to be obtained for said invention by the above application, for the United States of America and its territorial possessions and any other foreign country or countries that may be granted to them therefor, and any continuation, division, renewal, or substitute thereof, and as to letters patent any reissue or re-examination thereof;

ASSIGNOR(S) agree that this Assignment may be executed in one or more counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to constitute one and the same instrument.

ASSIGNOR(S) hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment;

ASSIGNOR(S) further covenant that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR(S) and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may

2

Docket No. 1-27908 CLIO 1083-91670

be necessary or desirable to carry out the purposes thereof.

Date: Jay. 26. 2024

ASSIGNORS: Nextgen Bioscience Co.

Signature

Bongyong LEE

Print

Chief executive officer

Title

NOTE: No witnessing, notarization or legalization is necessary. If the assignment is notarized or legalized, then it will only be prima facie evidence of execution. 35 U.S.C. 261.

3